as9核糖核蛋白递送的研究进展

he clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system as a revolutionary genome editing technology offers a powerful tool for scientific research and has great potential in the treatment of various diseases. As the development in gene editing technology progresses rapidly in recent years, CRISPR/Cas gene editing system emerged as one of the new generation of targeted genome editing technologies, alongside the zinc finger nucleases (ZFNs) system and transcription activator-like effector nucleases (TALENs) system.The CRISPR-associate protein9can be adapted to genome editing with a customized CRISPR RNA (crRNA) together with a common transactivating CRISPR RNA (tracrRNA) or an artificial single guide RNA (sgRNA) which was a chimeric crRNA-tracrRNA hybrid. However, since the delivered CRISPR/Cas9 cannot be efficiently delivered to the target cells, the translation of this biotechnology into therapy still faces considerable challenges. This paper will discuss the current delivery methods of Cas9 ribonucleoprotein (RNP), including physical delivery, viral vector and non-viral vector delivery, and prospect the development prospects of these delivery methods for intracellular delivery of Cas9 RNP, in order to provide a rationale for designing Generation materials provide theoretical reference.